Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: A United States perspective

Clinical Microbiology Reviews

Volumn 29, Issue 3, 2016, Pages 525-552

  Kim, Lindsay ^a   McGee, Lesley ^a   Tomczyk, Sara ^a   Beall, Bernard ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXAZOLIDINONE DERIVATIVE; BETA LACTAM DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; GAMMA GLUTAMYLTRANSFERASE; KETOLIDE; LINCOSAMIDE; MACROLIDE; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE; BETA LACTAM; VACCINE;

ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; COMMUNITY ACQUIRED PNEUMONIA; DRUG TOLERANCE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENE TRANSFER; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMOCOCCAL INFECTION; POLYMERASE CHAIN REACTION; PROTEIN BINDING; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; VACCINATION REACTION; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; PNEUMOCOCCAL INFECTIONS; PREVALENCE; UNITED STATES;

BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 84963715621     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00058-15     Document Type: Review

References (307)

1. Lynch JP, III, Zhanel GG. 2009. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 30:189–209. http://dx.doi.org/10.1055/s-0029-1202938.
2. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C, Child Health Epidemiology Reference Group of WHO and UNICEF. 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375:1969–1987. http://dx.doi.org/10.1016/S0140-6736(10)60549-1.
3. World Health Organization. 2014. Global immunization data. World Health Organization, Geneva, Switzerland. http://www.who.int/immunization/monitoring_surveillance/global_immunization_data.pdf?ua_1.Accessed17September2014.
4. Centers for Disease Control and Prevention. 1993. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immunoglobulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 42:1–18.
5. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWRMorb Mortal Wkly Rep 46:1–24.
6. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG, Active Bacterial Core Surveillance/Emerging Infections Program Network. 2001. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285:1729–1735. http://dx.doi.org/10.1001/jama.285.13.1729.
7. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. 2006. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495–1502. http://dx.doi.org/10.1016/S0140-6736(06)69637-2.
8. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR, Active Bacterial Core Surveillance/Emerging Infections Program Network. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32–41. http://dx.doi.org/10.1086/648593.
9. Morgenroth J, Kaufmann M. 1912. Arzneifestigkeit bei Bakterien (Pneumokokken). Z Immunitatsforsch Exp Ther 15:610.
10. Moore HF, Chesney AM. 1917. A study of ethylhydrocupreine (optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 19:611.
11. Ross RW. 1939. Acquired tolerance of pneumococcus to M. & B. 693. Lancet i:1207–1208.
12. Eriksen KR. 1945. Studies on induced resistance to penicillin in a pneumococcus type 1. Acta Pathol Microbiol Scand 22:398–401.
13. McKee CM, Houck CL. 1943. Induced resistance to penicillin of cultures of staphylococci, pneumococci, and streptococci. Proc Soc Exp Biol Med 53:33–34. http://dx.doi.org/10.3181/00379727-53-14172P.
14. Kislak JW, Razavi LM, Daly AK, Finland M. 1965. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 250:261–268. http://dx.doi.org/10.1097/00000441-196509000-00003.
15. Anderson P, Betts R. 1989. Human adult immunogenicity of proteincoupled pneumococcal capsular antigens of serotypes prevalent in otitis media. Pediatr Infect Dis J 8(Suppl 1):S50–S53.
16. Henderson FW, Gilligan PH, Wait K, Goff DA. 1988. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. J Infect Dis 157:256–263. http://dx.doi.org/10.1093/infdis/157.2.256.
17. Hansman D, Morris S. 1988. Pneumococcal carriage amongst children in Adelaide, South Australia. Epidemiol Infect 101:411–417. http://dx.doi.org/10.1017/S0950268800054364.
18. Klugman KP, Koornhof HJ, Kuhnle V. 1986. Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci. Am J Dis Child 140:1186–1190.
19. Pérez JL, Linares J, Bosch J, López de Goicoechea MJ, Martín R. 1987. Antibiotic resistance of Streptococcus pneumoniae in childhood carriers. J Antimicrob Chemother 19:278–280. http://dx.doi.org/10.1093/jac/19.2.278.
20. Klugman KP. 1990. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3:171–196.
21. Jones RN, Sader HS, Mendes RE, Flamm RK. 2013. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 75:107–109. http://dx.doi.org/10.1016/j.diagmicrobio.2012.08.024.
22. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, Miller GB, Witcomb MA, Isaäcson M, Ward JI, Austrian R. 1978. Emergence of multiply resistant pneumococci. N Engl J Med 299:735–740. http://dx.doi.org/10.1056/NEJM197810052991402.
23. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. 1998. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 4:325–337. http://dx.doi.org/10.1089/mdr.1998.4.325.
24. Koornhof HJ, Wasas A, Klugman K. 1992. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 15:84–94. http://dx.doi.org/10.1093/clinids/15.1.84.
25. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, Hakenbeck R, Hryniewicz W, Lefévre JC, Tomasz A, Klugman KP. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 39:2565–2571. http://dx.doi.org/10.1128/JCM.39.7.2565-2571.2001.
26. European Centre for Disease Prevention and Control. 2013. Annual epidemiological report 2012: reporting on 2010 surveillance data and 2011 epidemic intelligence data. European Centre for Disease Prevention and Control, Solna, Sweden.
27. Centers for Disease Control and Prevention. 2014. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
28. Reynolds CA, Finkelstein JA, Ray GT, Moore MR, Huang SS. 2014. Attributable healthcare utilization and cost of pneumonia due to drugresistant Streptococcus pneumoniae: a cost analysis. Antimicrob Resist Infect Control 3:16. http://dx.doi.org/10.1186/2047-2994-3-16.
29. Quach C, Weiss K, Moore D, Rubin E, McGeer A, Low DE. 2002. Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: resistant vs. susceptible strains. Int J Antimicrob Agents 20: 113–118. http://dx.doi.org/10.1016/S0924-8579(02)00127-9.
30. Einarsson S, Kristjansson M, Kristinsson KG, Kjartansson G, Jonsson S. 1998. Pneumonia caused by penicillin-non-susceptible and penicillinsusceptible pneumococci in adults: a case-control study. Scand J Infect Dis 30:253–256. http://dx.doi.org/10.1080/00365549850160882.
31. Klepser ME, Klepser DG, Ernst EJ, Brooks J, Diekema DJ, Mozaffari E, Hendrickson J, Doern GV. 2003. Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy 23:349–359. http://dx.doi.org/10.1592/phco.23.3.349.32105.
32. Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, Phelan M, Facklam RR, Cetron MS, Breiman RF, Kolczak M, Schuchat A. 2001. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 33:797–805. http://dx.doi.org/10.1086/322623.
33. Plouffe JF, Breiman RF, Facklam RR. 1996. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 275:194–198.
34. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF. 2000. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 30:520–528. http://dx.doi.org/10.1086/313716.
35. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.AmJ Public Health 90:223–229. http://dx.doi.org/10.2105/AJPH.90.2.223.
36. Edson DC, Glick T, Massey LD. 2006. Susceptibility testing practices for Streptococcus pneumoniae: results of a proficiency testing survey of clinical laboratories. Diagn Microbiol Infect Dis 55:225–230. http://dx.doi.org/10.1016/j.diagmicrobio.2006.01.010.
37. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
38. Centers for Disease Control and Prevention. 2008. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae— United States, 2006-2007. MMWR Morb Mortal Wkly Rep 57:1353–1355.
39. Carvalho MDG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G, Ades EW, Dagan R, Sampson JS. 2007. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol 45:2460–2466. http://dx.doi.org/10.1128/JCM.02498-06.
40. Harris KA, Turner P, Green EA, Hartley JC. 2008. Duplex real-time PCR assay for detection of Streptococcus pneumoniae in clinical samples and determination of penicillin susceptibility. J Clin Microbiol 46:2751–2758. http://dx.doi.org/10.1128/JCM.02462-07.
41. Srinivasan V, du Plessis M, Beall BW, McGee L. 2011. Quadriplex real-time polymerase chain reaction (lytA, mef, erm, pbp2b(wt)) for pneumococcal detection and assessment of antibiotic susceptibility. Diagn Microbiol Infect Dis 71:453–456. http://dx.doi.org/10.1016/j.diagmicrobio.2011.08.017.
42. Fukushima KY, Yanagihara K, Hirakata Y, Sugahara K, Morinaga Y, Kohno S, Kamihira S. 2008. Rapid identification of penicillin and macrolide resistance genes and simultaneous quantification of Streptococcus pneumoniae in purulent sputum samples by use of a novel real-time multiplex PCR assay. J Clin Microbiol 46:2384–2388. http://dx.doi.org/10.1128/JCM.00051-08.
43. Kearns AM, Graham C, Burdess D, Heatherington J, Freeman R. 2002. Rapid real-time PCR for determination of penicillin susceptibility in pneumococcal meningitis, including culture-negative cases. J Clin Microbiol 40:682–684. http://dx.doi.org/10.1128/JCM.40.2.682-684.2002.
44. Zettler EW, Scheibe RM, Dias CA, Santafé P, Santos DS, Moreira JDS, Fritscher CC. 2006. Determination of penicillin resistance in Streptococcus pneumoniae isolates from southern Brazil by PCR. Int J Infect Dis 10:110–115. http://dx.doi.org/10.1016/j.ijid.2005.04.005.
45. Cassone M, D’Andrea MM, Iannelli F, Oggioni MR, Rossolini GM, Pozzi G. 2006. DNA microarray for detection of macrolide resistance genes. Antimicrob Agents Chemother 50:2038–2041. http://dx.doi.org/10.1128/AAC.01574-05.
46. Haanperä M, Huovinen P, Jalava J. 2005. Detection and quantification of macrolide resistance mutations at positions 2058 and 2059 of the 23S rRNA gene by pyrosequencing. Antimicrob Agents Chemother 49:457–460. http://dx.doi.org/10.1128/AAC.49.1.457-460.2005.
47. Köser CU, Ellington MJ, Peacock SJ. 2014. Whole-genome sequencing to control antimicrobial resistance. Trends Genet 30:401–407. http://dx.doi.org/10.1016/j.tig.2014.07.003.
48. Chewapreecha C, Marttinen P, Croucher NJ, Salter SJ, Harris SR, Mather AE, Hanage WP, Goldblatt D, Nosten FH, Turner C, Turner P, Bentley SD, Parkhill J. 2014. Comprehensive identification of single nucleotide polymorphisms associated with β-lactam resistance within pneumococcal mosaic genes. PLoS Genet 10:e1004547. http://dx.doi.org/10.1371/journal.pgen.1004547.
49. Croucher NJ, Chewapreecha C, Hanage WP, Harris SR, McGee L, van der Linden M, Song JH, Ko KS, de Lencastre H, Turner C, Yang F, Sá-Leão R, Beall B, Klugman KP, Parkhill J, Turner P, Bentley SD. 2014. Evidence for soft selective sweeps in the evolution of pneumococcal multidrug resistance and vaccine escape. Genome Biol Evol 6:1589–1602. http://dx.doi.org/10.1093/gbe/evu120.
50. Metcalf BJ, Gertz RE, Gladstone RA, Walker H, Sherwood LK, Jackson D, Li Z, Law C, Hawkins PA, Chochua S, Sheth M, Rayamajhi N, Bentley SD, Kim L, Whitney CG, McGee L, Beall B. 2016. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect 22:60.e9–60.e29. http://dx.doi.org/10.1016/j.cmi.2015.08.027.
51. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM. 2014. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother 58:212–220. http://dx.doi.org/10.1128/AAC.01310-13.
52. Dowell SF, Schwartz B. 1997. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician 55:1647–1654.
53. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. 1999. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 103: E28. http://dx.doi.org/10.1542/peds.103.3.e28.
54. Klugman KP. 2007. Risk factors for antibiotic resistance in Streptococcus pneumoniae. S Afr Med J 97:1129–1132.
55. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF. 1995. The prevalence of drugresistant Streptococcus pneumoniae in Atlanta. N Engl J Med 333:481–486. http://dx.doi.org/10.1056/NEJM199508243330803.
56. Navarro Torné A, Dias JG, Quinten C, Hruba F, Busana MC, Lopalco PL, Gauci AJ, Pastore-Celentano L, ECDC Country Experts for Pneumococcal Disease. 2014. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 32:3644–3650. http://dx.doi.org/10.1016/j.vaccine.2014.04.066.
57. Doern GV, Pfaller MA, Erwin ME, Brueggemann AB, Jones RN. 1998. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada—1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 32:313–316. http://dx.doi.org/10.1016/S0732-8893(98)00081-9.
58. Schmitz FJ, Verhoef J, Fluit AC. 1999. Comparative activity of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates originating from 20 European university hospitals. SENTRY Participants Group. Eur J Clin Microbiol Infect Dis 18:450–453. http://dx.doi.org/10.1007/s100960050318.
59. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. 1998. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 27:764–770. http://dx.doi.org/10.1086/514953.
60. Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu W, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK, Thomas K, Perera J, Yee TT, Jamal F, Warsa UC, Vinh BX, Jacobs MR, Appelbaum PC, Pai CH. 1999. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis 28:1206–1211. http://dx.doi.org/10.1086/514783.
61. Fung CP, Hu BS, Lee SC, Liu PY, Jang TN, Leu HS, Kuo BI, Yen MY, Liu CY, Liu YC, Lau YJ, Yu KW. 2000. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an island-wide surveillance study between 1996 and 1997. J Antimicrob Chemother 45:49–55. http://dx.doi.org/10.1093/jac/45.1.49.
62. Zhang B, Gertz RE, Jr, Liu Z, Fu W, Beall B. 2012. Characterization of highly antimicrobial-resistant clinical pneumococcal isolates recovered in a Chinese hospital during 2009-2010. J Med Microbiol 61:42–48. http://dx.doi.org/10.1099/jmm.0.035675-0.
63. Crowther-Gibson P, Cohen C, Klugman KP, de Gouveia L, von Gottberg A, Group for Enteric Respiratory and Meningeal Disease Surveillance in South Africa. 2012. Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. Antimicrob Agents Chemother 56:5088–5095. http://dx.doi.org/10.1128/AAC.06463-11.
64. Nava JM, Bella F, Garau J, Lite J, Morera MA, Martí C, Fontanals D, Font B, Pineda V, Uriz S, Deulofeu F, Calderon A, Duran P, Grau M, Agudo A. 1994. Predictive factors for invasive disease due to penicillinresistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis 19:884–890. http://dx.doi.org/10.1093/clinids/19.5.884.
65. Wroe PC, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, Stevenson AE, Rifas-Shiman SL, Kleinman K, Dutta-Linn MM, Hinrichsen VL, Lakoma M, Huang SS. 2012. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 31:249–254. http://dx.doi.org/10.1097/INF.0b013e31824214ac.
66. Bédos JP, Chevret S, Chastang C, Geslin P, Régnier B. 1996. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 22:63–72. http://dx.doi.org/10.1093/clinids/22.1.63.
67. Brandileone MC, Casagrande ST, Guerra ML, Zanella RC, Andrade AL, Di Fabio JL. 2006. Increase in numbers of β-lactam-resistant invasive Streptococcus pneumoniae in Brazil and the impact of conjugate vaccine coverage. J Med Microbiol 55:567–574. http://dx.doi.org/10.1099/jmm.0.46387-0.
68. Clavo-Sánchez AJ, Girón-González JA, López-Prieto D, Canueto-Quintero J, Sánchez-Porto A, Vergara-Campos A, Marín-Casanova P, Córdoba-Doña JA. 1997. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 24:1052–1059. http://dx.doi.org/10.1086/513628.
69. Katsarolis I, Poulakou G, Analitis A, Matthaiopoulou I, Roilides E, Antachopoulos C, Kafetzis DA, Daikos GL, Vorou R, Koubaniou C, Pneumatikos I, Samonis G, Syriopoulou V, Giamarellou H, Kanellakopoulou K. 2009. Risk factors for nasopharyngeal carriage of drugresistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece. BMC Infect Dis 9:120. http://dx.doi.org/10.1186/1471-2334-9-120.
70. Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. 2007. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother 51:3491–3497. http://dx.doi.org/10.1128/AAC.01581-06.
71. Jacobs MR. 2007. Clinical significance of antimicrobial resistance in Streptococcus pneumoniae. S Afr Med J 97:1133–1140.
72. File TM. 2009. The science of selecting antimicrobials for communityacquired pneumonia (CAP). J Manag Care Pharm 15:S5–S11.
73. Feldman C, Anderson R. 2009. New insights into pneumococcal disease. Respirology 14:167–179. http://dx.doi.org/10.1111/j.1440-1843.2008.01422.x.
74. Anderson R, Theron AJ, Feldman C. 1996. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 20:693–705. http://dx.doi.org/10.1007/BF01488805.
75. Barnes PJ. 2007. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 119:1055–1062. http://dx.doi.org/10.1016/j.jaci.2007.01.015.
76. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr, Musher DM, Whitney C, Infectious Diseases Society of America. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433. http://dx.doi.org/10.1086/380488.
77. Kaplan SL. 2004. Review of antibiotic resistance, antibiotic treatment and prevention of pneumococcal pneumonia. Paediatr Respir Rev 5:S153–S158. http://dx.doi.org/10.1016/S1526-0542(04)90030-9.
78. Reid R, Jr, Bradley JS, Hindler J. 1995. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr Infect Dis J 14:1104–1105. http://dx.doi.org/10.1097/00006454-199512000-00016.
79. Jackson MA, Burry VF, Olson LC, Duthie SE, Kearns GL. 1996. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J 15:1049–1051. http://dx.doi.org/10.1097/00006454-199611000-00026.
80. Kelley MA, Weber DJ, Gilligan P, Cohen MS. 2000. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 31:1008–1011. http://dx.doi.org/10.1086/318157.
81. Bochud PY, Calandra T, Moreillon P, Baumgartner JD, Yersin B. 2001. Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media. Eur J Clin Microbiol Infect Dis 20:136–137. http://dx.doi.org/10.1007/PL00011244.
82. Mufson MA, Stanek RJ. 1999. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 107:34S–43S.
83. Waterer GW, Somes GW, Wunderink RG. 2001. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842. http://dx.doi.org/10.1001/archinte.161.15.1837.
84. Kaplan SL, Patterson L, Edwards KM, Azimi PH, Bradley JS, Blumer JL, Tan TQ, Lobeck FG, Anderson DC, Linezolid Pediatric Pneumonia Study Group, Pharmacia and Upjohn. 2001. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 20:488–494. http://dx.doi.org/10.1097/00006454-200105000-00004.
85. Jacobs MR. 2008. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 6:619–635. http://dx.doi.org/10.1586/14787210.6.5.619.
86. Hansman D, Bullen MM. 1967. A resistant pneumococcus. Lancet i:264–265.
87. Liñares J, Pallares R, Alonso T, Perez JL, Ayats J, Gudiol F, Viladrich PF, Martin R. 1992. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 15:99–105. http://dx.doi.org/10.1093/clinids/15.1.99.
88. Michel J, Dickman D, Greenberg Z, Bergner-Rabinowitz S. 1983. Serotype distribution of penicillin-resistant pneumococci and their susceptibilities to seven antimicrobial agents. Antimicrob Agents Chemother 23:397–401. http://dx.doi.org/10.1128/AAC.23.3.397.
89. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. 1991. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 163:1273–1278. http://dx.doi.org/10.1093/infdis/163.6.1273.
90. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. 1996. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention’s Pneumococcal Sentinel Surveillance System. J Infect Dis 174:986–993. http://dx.doi.org/10.1093/infdis/174.5.986.
91. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, Active Bacterial Core Surveillance of the Emerging Infections Program Network. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455–1463. http://dx.doi.org/10.1056/NEJMoa051642.
92. Tipper DJ, Strominger JL. 1965. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A 54:1133–1141. http://dx.doi.org/10.1073/pnas.54.4.1133.
93. Filipe SR, Pinho MG, Tomasz A. 2000. Characterization of the murMN operon involved in the synthesis of branched peptidoglycan peptides in Streptococcus pneumoniae. J Biol Chem 275:27768–27774.
94. Percheson PB, Bryan LE. 1980. Penicillin-binding components of penicillin- susceptible and -resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 18:390–396. http://dx.doi.org/10.1128/AAC.18.3.390.
95. Hakenbeck R, Tarpay M, Tomasz A. 1980. Multiple changes of penicillin- binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 17:364–371. http://dx.doi.org/10.1128/AAC.17.3.364.
96. Dowson CG, Hutchison A, Spratt BG. 1989. Extensive remodelling of the transpeptidase domain of penicillin binding protein 2B of a penicillinresistant South African isolate of Streptococcus pneumoniae. Mol Microbiol 3:95–102. http://dx.doi.org/10.1111/j.1365-2958.1989.tb00108.x.
97. Dowson CG, Hutchison A, Brannigan JA, George RC, Hansman D, Liñares J, Tomasz A, Smith JM, Spratt BG. 1989. Horizontal transfer of penicillin binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci U S A 86:8842–8846. http://dx.doi.org/10.1073/pnas.86.22.8842.
98. Coffey TJ, Dowson CG, Daniels M, Zhou J, Martin C, Spratt BG, Musser JM. 1991. Horizontal gene transfer of multiple penicillinbinding protein genes, and capsular biosynthetic genes in natural populations of Streptococcus pneumoniae. Mol Microbiol 5:2255–2260. http://dx.doi.org/10.1111/j.1365-2958.1991.tb02155.x.
99. Muñoz R, Dowson CG, Daniels M. 1992. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae. Mol Microbiol 6:2461–2465.
100. Barcus VA, Ghanekar K, Yeo M, Coffey TJ, Dowson CG. 1995. Genetics of high level penicillin resistance in clinical isolates of Streptococcus pneumoniae. FEMS Microbiol Lett 126:299–303. http://dx.doi.org/10.1111/j.1574-6968.1995.tb07433.x.
101. Gordon E, Mouz N, Duée E, Dideberg O. 2000. The crystal structure of the penicillin-binding protein 2x from Streptococcus pneumoniae and its acyl-enzyme form: implication in drug resistance. J Mol Biol 299:477–485. http://dx.doi.org/10.1006/jmbi.2000.3740.
102. Contreras-Martel C, Job V, Di Guilmi AM, Vernet T, Dideberg O, Dessen A. 2006. Crystal structure of penicillin-binding protein 1a (PBP1a) reveals a mutational hotspot implicated in β-lactam resistance in Streptococcus pneumoniae. J Mol Biol 355:684–696. http://dx.doi.org/10.1016/j.jmb.2005.10.030.
103. Contreras-Martel C, Dahout-Gonzalez C, Martins ADS, Kotnik M, Dessen A. 2009. PBP active site flexibility as the key mechanism for β-lactam resistance in pneumococci. J Mol Biol 387:899–909. http://dx.doi.org/10.1016/j.jmb.2009.02.024.
104. Kell CM, Sharma UK, Dowson CG, Town C, Balganesh TS, Spratt BG. 1993. Deletion analysis of the essentiality of penicillin-binding proteins 1A, 2B and 2X of Streptococcus pneumoniae. FEMS Microbiol Lett 106: 171–175. http://dx.doi.org/10.1111/j.1574-6968.1993.tb05954.x.
105. Pato MV, Carvalho CB, Tomasz A. 1995. Antibiotic susceptibility of Streptococcus pneumoniae isolates in Portugal. A multicenter study between 1989 and 1993. Microb Drug Resist 1:59–69.
106. Muñoz R, Coffey TJ, Daniels M, Dowson CG, Laible G, Casal J, Hakenbeck R, Jacobs M, Musser JM, Spratt BG, Tomasz A. 1991. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 164:302–306. http://dx.doi.org/10.1093/infdis/164.2.302.
107. Munoz R, Musser JM, Crain M, Briles DE, Marton A, Parkinson AJ, Sorensen U, Tomasz A. 1992. Geographic distribution of penicillinresistant clones of Streptococcus pneumoniae: characterisation by penicillin- binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis 15:112–118. http://dx.doi.org/10.1093/clinids/15.1.112.
108. McDougal LK, Rasheed JK, Biddle JW, Tenover FC. 1995. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 39:2282–2288. http://dx.doi.org/10.1128/AAC.39.10.2282.
109. Gherardi G, Whitney CG, Facklam RR, Beall B. 2000. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles. J Infect Dis 181:216–229. http://dx.doi.org/10.1086/315194.
110. Richter SS, Heilmann KP, Coffman SL, Huynh HK, Brueggemann AB, Pfaller MA, Doern GV. 2002. The molecular epidemiology of penicillinresistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 34:330–339. http://dx.doi.org/10.1086/338065.
111. Gertz RE, Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA, Facklam RR, Besser JM, Harrison LH, Whitney CG, Beall B. 2003. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41:4194–4216. http://dx.doi.org/10.1128/JCM.41.9.4194-4216.2003.
112. Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. 2011. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis 203:1360–1368. http://dx.doi.org/10.1093/infdis/jir052.
113. Hakenbeck R, Tornette S, Adkinson NF. 1987. Interaction of non-lytic b-lactams with penicillin-binding proteins in Streptococcus pneumoniae. J Gen Microbiol 133:755–760.
114. Grebe T, Hakenbeck R. 1996. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics. Antimicrob Agents Chemother 40: 829–834.
115. Hakenbeck R, Brückner R, Denapaite D, Maurer P. 2012. Molecular mechanisms of β-lactam resistance in Streptococcus pneumoniae. Future Microbiol 7:395–410. http://dx.doi.org/10.2217/fmb.12.2.
116. Krauss J, van der Linden M, Grebe T, Hakenbeck R. 1996. Penicillinbinding proteins 2x and 2b as primary PBP-targets in Streptococcus pneumoniae. Microb Drug Resist 2:183–186. http://dx.doi.org/10.1089/mdr.1996.2.183.
117. Coffey TJ, Daniels M, McDougal LK, Dowson CG, Tenover FC, Spratt BG. 1995. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 39:1306–1313. http://dx.doi.org/10.1128/AAC.39.6.1306.
118. Schrag SJ, McGee L, Whitney CG, Beall B, Craig AS, Choate ME, Jorgensen JH, Facklam RR, Klugman KP, Active Bacterial Core Surveillance Team. 2004. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 48:3016–3023. http://dx.doi.org/10.1128/AAC.48.8.3016-3023.2004.
119. du Plessis M, Smith AM, Klugman KP. 2000. Analysis of penicillinbinding protein lb and 2a genes from Streptococcus pneumoniae. Microb Drug Resist 6:127–131. http://dx.doi.org/10.1089/107662900419438.
120. Hakenbeck R. 1999. -lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol 33:673–678. http://dx.doi.org/10.1046/j.1365-2958.1999.01521.x.
121. Smith AM, Klugman KP. 2000. Non-penicillin-binding protein mediated high-level penicillin and cephalosporin resistance in a Hungarian clone of Streptococcus pneumoniae. Microb Drug Resist 6:105–110. http://dx.doi.org/10.1089/107662900419401.
122. Chesnel L, Carapito R, Croizé J, Dideberg O, Vernet T, Zapun A. 2005. Identical penicillin-binding domains in penicillin-binding proteins of Streptococcus pneumoniae clinical isolates with different levels of β-lactam resistance. Antimicrob Agents Chemother 49:2895–2902. http://dx.doi.org/10.1128/AAC.49.7.2895-2902.2005.
123. Filipe SR, Tomasz A. 2000. Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes. Proc Natl Acad Sci U S A 97:4891–4896. http://dx.doi.org/10.1073/pnas.080067697.
124. Sauerbier J, Maurer P, Rieger M, Hakenbeck R. 2012. Streptococcus pneumoniae R6 interspecies transformation: genetic analysis of penicillin resistance determinants and genome-wide recombination events. Mol Microbiol 86:692–706. http://dx.doi.org/10.1111/mmi.12009.
125. Filipe SR, Severina E, Tomasz A. 2000. Distribution of the mosaic structured murM genes among natural populations of Streptococcus pneumoniae. J Bacteriol 182:6798–6805. http://dx.doi.org/10.1128/JB.182.23.6798-6805.2000.
126. Garcia-Bustos J, Tomasz A. 1990. A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillinresistant pneumococci. Proc Natl Acad SciUSA87:5415–5419. http://dx.doi.org/10.1073/pnas.87.14.5415.
127. Smith AM, Klugman KP. 2001. Alterations in MurMN, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 45:2393–2396. http://dx.doi.org/10.1128/AAC.45.8.2393-2396.2001.
128. Berg KH, Stamsås GA, Straume D, Håvarstein LS. 2013. Effects of low PBP2b levels on cell morphology and peptidoglycan composition in Streptococcus pneumoniae R6. J Bacteriol 195:4342–4354. http://dx.doi.org/10.1128/JB.00184-13.
129. Crisóstomo MI, Vollmer W, Kharat AS, Inhülsen S, Gehre F, Buckenmaier S, Tomasz A. 2006. Attenuation of penicillin resistance in a peptidoglycan O-acetyl transferase mutant of Streptococcus pneumoniae. Mol Microbiol 61:1497–1509. http://dx.doi.org/10.1111/j.1365-2958.2006.05340.x.
130. Tait-Kamradt AG, Cronan M, Dougherty TJ. 2009. Comparative genome analysis of high-level penicillin resistance in Streptococcus pneumoniae. Microb Drug Resist 15:69–75. http://dx.doi.org/10.1089/mdr.2009.0891.
131. Beilharz K, Nováková L, Fadda D, Branny P, Massidda O, Veening JW. 2012. Control of cell division in Streptococcus pneumoniae by the conserved Ser/Thr protein kinase StkP. Proc Natl Acad Sci U S A 109: E905–E913. http://dx.doi.org/10.1073/pnas.1119172109.
132. Morlot C, Bayle L, Jacq M, Fleurie A, Tourcier G, Galisson F, Vernet T, Grangeasse C, Di Guilmi AM. 2013. Interaction of penicillin-binding protein 2x and Ser/Thr protein kinase StkP, two key players in Streptococcus pneumoniae R6 morphogenesis. Mol Microbiol 90:88–102. http://dx.doi.org/10.1111/mmi.12348.
133. Dias R, Félix D, Caniça M, Trombe MC. 2009. The highly conserved serine threonine kinase StkP of Streptococcus pneumoniae contributes to penicillin susceptibility independently from genes encoding penicillinbinding proteins. BMC Microbiol 9:121. http://dx.doi.org/10.1186/1471-2180-9-121.
134. Müller M, Marx P, Hakenbeck R, Brückner R. 2011. Effect of new alleles of the histidine kinase gene ciaH on the activity of the response regulator CiaR in Streptococcus pneumoniae R6. Microbiology 157:3104–3112. http://dx.doi.org/10.1099/mic.0.053157-0.
135. Edman M, Berg S, Storm P, Wikström M, Vikström S, Ohman A, Wieslander A. 2003. Structural features of glycosyltransferases synthesizing major bilayer and nonbilayer-prone membrane lipids in Acholeplasma laidlawii and Streptococcus pneumoniae. J Biol Chem 278:8420–84288. http://dx.doi.org/10.1074/jbc.M211492200.
136. Grebe T, Paik J, Hakenbeck R. 1997. A novel resistance mechanism against β-lactams in Streptococcus pneumoniae involves CpoA, a putative glycosyltransferase. J Bacteriol 179:3342–3349.
137. Medina MJ, Greene CM, Gertz RE, Facklam RR, Jagero G, Hamel M, Shi YP, Slutsker L, Feikin DR, Beall B. 2005. Novel antibiotic-resistant pneumococcal strains recovered from the upper respiratory tracts of HIV-infected adults and their children in Kisumu, Kenya. Microb Drug Resist 11:9–17. http://dx.doi.org/10.1089/mdr.2005.11.9.
138. Vallès X, Flannery B, Roca A, Mandomando I, Sigaúque B, Sanz S, Schuchat A, Levine M, Soriano-Gabarró M, Alonso P. 2006. Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique. Trop Med Int Health 11:358–366. http://dx.doi.org/10.1111/j.1365-3156.2006.01565.x.
139. Schaumburg F, Alabi A, von Eiff C, Flamen A, Traore H, Grobusch MP, Peters G, Kremsner PG, van der Linden M. 2013. Streptococcus pneumoniae colonization in remote African Pygmies. Trans R Soc Trop Med Hyg 107:105–109. http://dx.doi.org/10.1093/trstmh/trs018.
140. Arason VA, Kristinsson KG, Sigurdsson JA, Stefánsdóttir G, Mölstad S, Gudmundsson S. 1996. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 313:387–391.
141. Ruhe JJ, Hasbun R. 2003. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 36:1132–1138. http://dx.doi.org/10.1086/374556.
142. Pallares R, Gudiol F, Liñares J, Ariza J, Rufi G, Murgui L, Dorca J, Viladrich PF. 1987. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 317:18–22. http://dx.doi.org/10.1056/NEJM198707023170104.
143. Gray BM, Converse GM, III, Dillon HC, Jr. 1980. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 142:923–933. http://dx.doi.org/10.1093/infdis/142.6.923.
144. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y. 1997. Relationship between nasopharyngeal colonization and the development of otitis media in children. J Infect Dis 175:1440–1445. http://dx.doi.org/10.1086/516477.
145. Dowson CG. 2005. Genetic exchange in the respiratory tract, p 131–140. In Nataro JP, Cohen PS, Mobley HLT, Weiser JN (ed), Colonization of mucosal surfaces, 1st ed. ASM Press, Washington, DC.
146. Feil EJ, Smith JM, Enright MC, Spratt BG. 2000. Estimating recombinational parameters in Streptococcus pneumoniae from multilocus sequence typing data. Genetics 154:1439–1450.
147. Dowson CG, Coffey TJ, Kell C, Whiley RA. 1993. Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae. Mol Microbiol 9:635–643. http://dx.doi.org/10.1111/j.1365-2958.1993.tb01723.x.
148. Sibold C, Henrichsen J, König A, Martin C, Chalkley L, Hakenbeck R. 1994. Mosaic pbpX genes of major clones of penicillin-resistant Streptococcus pneumoniae have evolved from pbpX genes of a penicillin-sensitive Streptococcus oralis. Mol Microbiol 12:1013–1023. http://dx.doi.org/10.1111/j.1365-2958.1994.tb01089.x.
149. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891–894.
150. Carvalho MDG, Pimenta FC, Moura I, Roundtree A, Gertz RE, Jr, Li Z, Jagero G, Bigogo G, Junghae M, Conklin L, Feikin DR, Breiman RF, Whitney CG, Beall BW. 2013. Non-pneumococcal mitis-group streptococci confound detection of pneumococcal capsular serotype-specific loci in upper respiratory tract. PeerJ 1:e97. http://dx.doi.org/10.7717/peerj.97.
151. Mouz N, Di Guilmi AM, Gordon E, Hakenbeck R, Dideberg O, Vernet T. 1999. Mutations in the active site of penicillin-binding protein PBP2x from Streptococcus pneumoniae. Role in the specificity for β-lactam antibiotics. J Biol Chem 274:19175–19180.
152. Pernot L, Chesnel L, Le Gouellec A, Croizé J, Vernet T, Dideberg O, Dessen A. 2004. A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to β-lactam antibiotics. J Biol Chem 279:16463–16470. http://dx.doi.org/10.1074/jbc.M313492200.
153. Hakenbeck R, König A, Kern I, van der Linden M, Keck W, Billot-Klein D, Legrand R, Schoot B, Gutmann L. 1998. Acquisition of five high-Mr penicillin-binding protein variants during transfer of high level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol 180:1831–1840.
154. Enright MC, Spratt BG. 1999. Extensive variation in the ddl gene of penicillin- resistant Streptococcus pneumoniae results from a hitchhiking effect driven by the penicillin-binding protein 2b gene. Mol Biol Evol 16:1687–1695. http://dx.doi.org/10.1093/oxfordjournals.molbev.a026082.
155. Wyres KL, Lambertsen LM, Croucher NJ, McGee L, von Gottberg A, Liñares J, Jacobs MR, Kristinsson KG, Beall BW, Klugman KP, Parkhill J, Hakenbeck R, Bentley SD, Brueggemann AB. 2013. Pneumococcal capsular switching: a historical perspective. J Infect Dis 207:439–449. http://dx.doi.org/10.1093/infdis/jis703.
156. Coffey TJ, Enright MC, Daniels M, Morona JK, Morona R, Hryniewicz W, Paton JC, Spratt BG. 1998. Recombinational exchanges at the capsular polysaccharide biosynthetic locus leads to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 27:73–83. http://dx.doi.org/10.1046/j.1365-2958.1998.00658.x.
157. Griffith F. 1928. The significance of pneumococcal types. J Hyg (Lond) 27:113–159.
158. Avery OT, Macleod CM, McCarty M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79:137–158. http://dx.doi.org/10.1084/jem.79.2.137.
159. Trzciński K, Thompson CM, Lipsitch M. 2004. Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae. J Bacteriol 186:3447–3452. http://dx.doi.org/10.1128/JB.186.11.3447-3452.2004.
160. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, Active Bacterial Core Surveillance Team. 2005. Post vaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192:1988–1995. http://dx.doi.org/10.1086/498043.
161. Brueggemann AB, Pai R, Crook DW, Beall B. 2007. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 3:e168. http://dx.doi.org/10.1371/journal.ppat.0030168.
162. Moore MR, Gertz RE, Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B. 2008. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197:1016–1027. http://dx.doi.org/10.1086/528996.
163. Golubchik T, Brueggemann AB, Street T, Gertz RE, Jr, Spencer CC, Ho T, Giannoulatou E, Link-Gelles R, Harding RM, Beall B, Peto TE, Moore MR, Donnelly P, Crook DW, Bowden R. 2012. Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event. Nat Genet 44:352–355. http://dx.doi.org/10.1038/ng.1072.
164. Porat N, Arguedas A, Spratt BG, Trefler R, Brilla E, Loaiza C, Godoy D, Bilek N, Dagan R. 2004. Emergence of penicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis 190:2154–2161. http://dx.doi.org/10.1086/425908.
165. Hiller NL, Ahmed A, Powell E, Martin DP, Eutsey R, Earl J, Janto B, Boissy RJ, Hogg J, Barbadora K, Sampath R, Lonergan S, Post JC, Hu FZ, Ehrlich GD. 2010. Generation of genic diversity among Streptococcus pneumoniae strains via horizontal gene transfer during a chronic polyclonal pediatric infection. PLoS Pathog 6:e1001108. http://dx.doi.org/10.1371/journal.ppat.1001108.
166. Beall B, McEllistrem MC, Gertz RE, Jr, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG, Active Bacterial Core Surveillance Team. 2006. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44:999–1017. http://dx.doi.org/10.1128/JCM.44.3.999-1017.2006.
167. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. 2002. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 50(Suppl 1):25–37. http://dx.doi.org/10.1093/jac/dkf808.
168. Felmingham D, Cantón R, Jenkins SG. 2007. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 55:111–118. http://dx.doi.org/10.1016/j.jinf.2007.04.006.
169. Tomczyk SM, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, Holtxman C, Zansky SM, Thomas A, Baumbach J, Harrison LH, Farley MM, Beall B, McGee L, Gierke R, Pondo T, Kim L. 7 February 2016. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis http://dx.doi.org/10.1093/cid/ciw067.
170. Weisblum B. 1995. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 39:577–585. http://dx.doi.org/10.1128/AAC.39.3.577.
171. Farrell DJ, Morrissey I, Bakker S, Felmingham D. 2002. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 50:39–47. http://dx.doi.org/10.1093/jac/dkf806.
172. Hawkins PA, Chochua S, Jackson D, Beall B, McGee L. 2015. Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States. Microb Drug Resist 21:121–129. http://dx.doi.org/10.1089/mdr.2014.0086.
173. Varaldo PE, Montanari MP, Giovanetti E. 2009. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother 53:343–353. http://dx.doi.org/10.1128/AAC.00781-08.
174. Montanari MP, Giovanetti E, Cochetti I. 2006. An unexpressed tet(M) gene is present in the vast majority of tetracycline-susceptible streptococci carrying erm(B), p 129. Abstr 46th Intersci Conf Antimicrob Agents Chemother.
175. Davies TA, Bush K, Sahm D, Evangelista A. 2005. Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000. Antimicrob Agents Chemother 49:3031–3033. http://dx.doi.org/10.1128/AAC.49.7.3031-3033.2005.
176. Cochetti I, Vecchi M, Mingoia M, Tili E, Catania MR, Manzin A, Varaldo PE, Montanari MP. 2005. Molecular characterization of pneumococci with efflux-mediated erythromycin resistance and identification of a novel mef gene subclass, mef(I). Antimicrob Agents Chemother 49:4999–5006. http://dx.doi.org/10.1128/AAC.49.12.4999-5006.2005.
177. Santagati M, Iannelli F, Cascone C, Campanile F, Oggioni MR, Stefani S, Pozzi G. 2003. The novel conjugative transposon Tn1207.3 carries the macrolide efflux gene mef(A) in Streptococcus pyogenes. Microb Drug Resist 9:243–247. http://dx.doi.org/10.1089/107662903322286445.
178. Gay K, Stephens DS. 2001. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J Infect Dis 184:56–65. http://dx.doi.org/10.1086/321001.
179. Mingoia M, Vecchi M, Cochetti I, Tili E, Vitali LA, Manzin A, Varaldo PE, Montanari MP. 2007. Composite structure of Streptococcus pneumoniae containing the erythromycin efflux resistance gene mef(I) and the chloramphenicol resistance gene catQ. Antimicrob Agents Chemother 51:3983–3987. http://dx.doi.org/10.1128/AAC.00790-07.
180. Bley C, van der Linden M, Reinert RR. 2011. mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany. Int J Antimicrob Agents 37:425–431. http://dx.doi.org/10.1016/j.ijantimicag.2011.01.019.
181. Simoens S, Verhaegen J, van Bleyenbergh P, Peetermans WE, Decramer M. 2011. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones. Antimicrob Agents Chemother 55:3051–3053. http://dx.doi.org/10.1128/AAC.00019-11.
182. Domenech A, Tirado-Vélez JM, Fenoll A, Ardanuy C, Yuste J, Liñares J, de la Campa AG. 2014. Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006. Antimicrob Agents Chemother 58:2393–2399. http://dx.doi.org/10.1128/AAC.02669-13.
183. Ip M, Chau SS, Chi F, Cheuk ES, Ma H, Lai RW, Chan PK. 2007. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005. Antimicrob Agents Chemother 51:2192–2194. http://dx.doi.org/10.1128/AAC.00139-07.
184. Wang H, Chen M, Xu Y, Sun H, Yang Q, Hu Y, Cao B, Chu Y, Liu Y, Zhang R, Yu Y, Sun Z, Zhuo C, Ni Y, Hu B, Tan TY, Hsueh PR, Wang JH, Ko WC, Chen YH, Wahjono H. 2011. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009- 2010. Int J Antimicrob Agents 38:376–383. http://dx.doi.org/10.1016/j.ijantimicag.2011.06.015.
185. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 34:82–85. http://dx.doi.org/10.1016/j.ijantimicag.2009.02.002.
186. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750. http://dx.doi.org/10.1056/NEJMoa012122.
187. Anderson KB, Tan JS, File TM, Jr, DiPersio JR, Willey BM, Low DE. 2003. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 37:376–381. http://dx.doi.org/10.1086/376642.
188. Ho PL, Yam WC, Cheung TK, Ng WW, Que TL, Tsang DN, Ng TK, Seto WH. 2001. Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerg Infect Dis 7:906–908. http://dx.doi.org/10.3201/eid0705.010526.
189. Pestova E, Millichap JJ, Siddiqui F, Noskin GA, Peterson LR. 2002. Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae. J Antimicrob Chemother 49:553–556. http://dx.doi.org/10.1093/jac/49.3.553.
190. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. 2002. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother 49:893–895. http://dx.doi.org/10.1093/jac/dkf047.
191. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. 2003. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9:833–837. http://dx.doi.org/10.3201/eid0907.020589.
192. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. 1996. Highlevel fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 40:2760–2764.
193. Pan XS, Fisher LM. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol 178:4060–4069.
194. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, Flamm R, Doern GV. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 46:680–688. http://dx.doi.org/10.1128/AAC.46.3.680-688.2002.
195. Weigel LM, Anderson GJ, Facklam RR, Tenover FC. 2001. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45:3517–3523. http://dx.doi.org/10.1128/AAC.45.12.3517-3523.2001.
196. Pletz MW, Fugit RV, McGee L, Glasheen JJ, Keller DL, Welte T, Klugman KP. 2006. Fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis 12:1462–1463. http://dx.doi.org/10.3201/eid1209.051400.
197. Duesberg CB, Welte T, Pletz MW. 2007. The Lys137Asn mutation as surrogate marker for developing fluoroquinolone resistance in Streptococcus pneumoniae. J Chemother 19:750–751. http://dx.doi.org/10.1179/joc.2007.19.6.750.
198. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 41:1973–1978.
199. Baylay AJ, Ivens A, Piddock LJ. 2015. A novel gene amplification causes upregulation of the PatAB ABC transporter and fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 59: 3098–3108. http://dx.doi.org/10.1128/AAC.04858-14.
200. Andersen CL, Holland IB, Jacq A. 2006. Verapamil, a Ca2+ channel inhibitor acts as a local anesthetic and induces the sigma E dependent extra-cytoplasmic stress response in E. coli. Biochim Biophys Acta 1758: 1587–1595. http://dx.doi.org/10.1016/j.bbamem.2006.05.022.
201. Pletz MW, Michaylov N, Schumacher U, van der Linden M, Duesberg CB, Fuehner T, Klugman KP, Welte T, Makarewicz O. 2013. Antihypertensives suppress the emergence of fluoroquinolone-resistant mutants in pneumococci: an in vitro study. Int J Med Microbiol 303:176–181. http://dx.doi.org/10.1016/j.ijmm.2013.02.014.
202. Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L. 1999. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis 180:555–558. http://dx.doi.org/10.1086/314888.
203. Tankovic J, Perichon B, Duval J, Courvalin P. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 40:2505–2510.
204. Martín-Galiano AJ, Balsalobre L, Fenoll A, de la Campa AG. 2003. Genetic characterization of optochin-susceptible viridans group streptococci. Antimicrob Agents Chemother 47:3187–3194. http://dx.doi.org/10.1128/AAC.47.10.3187-3194.2003.
205. Bast DJ, de Azavedo JC, Tam TY, Kilburn L, Duncan C, Mandell LA, Davidson RJ, Low DE. 2001. Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 45:2631–2634. http://dx.doi.org/10.1128/AAC.45.9.2631-2634.2001.
206. Pletz MW, McGee L, Beall B, Whitney CG, Klugman KP. 2005. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 49:779–780. http://dx.doi.org/10.1128/AAC.49.2.779-780.2005.
207. Balsalobre L, Ferrándiz MJ, Liñares J, Tubau F, de la Campa AG. 2003. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 47:2072–2081. http://dx.doi.org/10.1128/AAC.47.7.2072-2081.2003.
208. Pletz MW, McGee L, Jorgensen J, Beall B, Facklam RR, Whitney CG, Klugman KP. 2004. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 48: 3491–3497. http://dx.doi.org/10.1128/AAC.48.9.3491-3497.2004.
209. Canton R, Morosini M, Enright MC, Morrissey I. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone- resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52:944–952. http://dx.doi.org/10.1093/jac/dkg465.
210. Hsueh PR, Teng LJ, Lee CM, Huang WK, Wu TL, Wan JH, Yang D, Shyr JM, Chuang YC, Yan JJ, Lu JJ, Wu JJ, Ko WC, Chang FY, Yang YC, Lau YJ, Liu YC, Leu HS, Liu CY, Luh KT, SMART Program 2001 Data. 2003. Telithromycin and quinupristine-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 data. Antimicrob Agents Chemother 47:2152–2157.
211. Montanari MP, Tili E, Cochetti I, Mingoia M, Manzin A, Varaldo PE. 2004. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb Drug Resist 10:209–217. http://dx.doi.org/10.1089/mdr.2004.10.209.
212. Wyres KL, van Tonder A, Lambertsen LM, Hakenbeck R, Parkhill J, Bentley SD, Brueggemann AB. 2013. Evidence of antimicrobial resistance- conferring genetic elements among pneumococci isolated prior to 1974. BMC Genomics 14:500. http://dx.doi.org/10.1186/1471-2164-14-500.
213. Burdett V, Inamine J, Rajagopalan S. 1982. Heterogeneity of tetracycline resistance determinants in Streptococcus. J Bacteriol 149:995–1004.
214. Widdowson CA, Klugman KP, Hanslo D. 1996. Identification of the tetracycline resistance gene, tet(O), in Streptococcus pneumoniae. Antimicrob Agents Chemother 40:2891–2893.
215. Oggioni MR, Dowson CG, Smith JM, Provvedi R, Pozzi G. 1996. The tetracycline resistance gene tet(M) exhibits mosaic structure. Plasmid 35:156–163. http://dx.doi.org/10.1006/plas.1996.0018.
216. Doherty N, Trzcinski K, Pickerill P, Zawadzki P, Dowson CG. 2000. Genetic diversity of the tet(M) gene in tetracycline-resistant clonal lineages of Streptococcus pneumoniae. Antimicrob Agents Chemother 44: 2979–2984. http://dx.doi.org/10.1128/AAC.44.11.2979-2984.2000.
217. Dzierzanowska-Fangrat K, Semczuk K, Górska P, Giedrys-Kalemba S, Kochman M, Samet A, Tyski S, Dzierzanowska D, Trzciński K. 2006. Evidence for tetracycline resistance determinant tet(M) allele replacement in a Streptococcus pneumoniae population of limited geographical origin. Int J Antimicrob Agents 27:159–164. http://dx.doi.org/10.1016/j.ijantimicag.2005.10.003.
218. Doern GV, Brueggemann A, Holley HP, Jr, Rauch AM. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208–1213.
219. Marchese A, Mannelli S, Tonoli E, Gorlero F, Toni M, Schito GC. 2001. Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997-1999). Microb Drug Resist 7:277–287. http://dx.doi.org/10.1089/10766290152652837.
220. Ferrándiz MJ, Ardanuy C, Liñares J, Balsalobre L, García MT, de la Campa AG. 2011. New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae. Antimicrob Agents Chemother 55:368–372. http://dx.doi.org/10.1128/AAC.00856-10.
221. Ayoubi P, Kilic AO, Vijayakumar MN. 1991. Tn5253, the pneumococcal omega (cat tet) BM6001 element, is a composite structure of two conjugative transposons, Tn5251 and Tn5252. J Bacteriol 173:1617–1622.
222. Widdowson CA, Adrian PV, Klugman KP. 2000. Acquisition of chloramphenicol resistance by the linearization and integration of the entire staphylococcal plasmid pC194 into the chromosome of Streptococcus pneumoniae. Antimicrob Agents Chemother 44:393–395. http://dx.doi.org/10.1128/AAC.44.2.393-395.2000.
223. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF. 2003. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 9:590–599. http://dx.doi.org/10.1046/j.1469-0691.2003.00573.x.
224. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. 2006. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 56:69–74. http://dx.doi.org/10.1016/j.diagmicrobio.2005.12.008.
225. Adrian PV, Klugman KP. 1997. Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 41:2406–2413.
226. Maskell JP, Sefton AM, Hall LM. 2001. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 45:1104–1108. http://dx.doi.org/10.1128/AAC.45.4.1104-1108.2001.
227. Lopez P, Espinosa M, Greenberg B, Lacks SA. 1987. Sulfonamide resistance in Streptococcus pneumoniae: DNA sequence of the gene encoding dihydropteroate synthase and characterization of the enzyme. J Bacteriol 169:4320–4326.
228. Maskell JP, Sefton AM, Hall LM. 1997. Mechanism of sulfonamide resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 41:2121–2126.
229. Padayachee T, Klugman KP. 1999. Novel expansions of the gene encoding dihydropteroate synthase in trimethoprim-sulfamethoxazoleresistant Streptococcus pneumoniae. Antimicrob Agents Chemother 43: 2225–2230.
230. Feikin DR, Dowell SF, Nwanyanwu OC, Klugman KP, Kazembe PN, Barat LM, Graf C, Bloland PB, Ziba C, Huebner RE, Schwartz B. 2000. Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis 181:1501–1505. http://dx.doi.org/10.1086/315382.
231. Schmitz FJ, Perdikouli M, Beeck A, Verhoef J, Fluit AC, European SENTRY Participants. 2001. Resistance to trimethoprimsulfamethoxazole and modifications in genes coding for dihydrofolate reductase and dihydropteroate synthase in European Streptococcus pneumoniae isolates. J Antimicrob Chemother 48:935–936. http://dx.doi.org/10.1093/jac/48.6.935.
232. Lonks JR, Goldman DA. 2005. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 40:1657–1664. http://dx.doi.org/10.1086/430067.
233. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother 54:230–238. http://dx.doi.org/10.1128/AAC.01123-09.
234. Wilson DN. 2011. On the specificity of antibiotics targeting the large ribosomal subunit. Ann N Y Acad Sci 1241:1–16. http://dx.doi.org/10.1111/j.1749-6632.2011.06192.x.
235. Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE. 2009. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 64:659–660. http://dx.doi.org/10.1093/jac/dkp231.
236. Leclercq R, Courvalin P. 2002. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 46:2727–2734. http://dx.doi.org/10.1128/AAC.46.9.2727-2734.2002.
237. Walsh F, Willcock J, Amyes S. 2003. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother 52:345–353. http://dx.doi.org/10.1093/jac/dkg348.
238. Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D. 2004. In vitro activities of telithromycin, linezolid, and quinupristindalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 48:3169–3171. http://dx.doi.org/10.1128/AAC.48.8.3169-3171.2004.
239. Reinert RR, van der Linden M, Al-Lahham A. 2005. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany. Antimicrob Agents Chemother 49:3520–3522. http://dx.doi.org/10.1128/AAC.49.8.3520-3522.2005.
240. Tait-Kamradt A, Davies T, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, Wondrack L, Walker A, Jacobs MR, Sutcliffe J. 2000. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 44:3395–3401. http://dx.doi.org/10.1128/AAC.44.12.3395-3401.2000.
241. Faccone D, Andres P, Galas M, Tokumoto M, Rosato A, Corso A. 2005. Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones. J Clin Microbiol 43: 5800–5803. http://dx.doi.org/10.1128/JCM.43.11.5800-5803.2005.
242. Pérez-Trallero E, Marimon JM, Iglesias L, Larruskain J. 2003. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 9:1159–1162. http://dx.doi.org/10.3201/eid0909.020810.
243. Wolter N, Smith AM, Low DE, Klugman KP. 2007. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 51:1092–1095. http://dx.doi.org/10.1128/AAC.01153-06.
244. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. 2005. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 49:5024–5032. http://dx.doi.org/10.1128/AAC.49.12.5024-5032.2005.
245. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis 76:206–213. http://dx.doi.org/10.1016/j.diagmicrobio.2013.01.025.
246. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother 57:1077–1081. http://dx.doi.org/10.1128/AAC.02112-12.
247. Meka VG, Gold HS. 2004. Antimicrobial resistance to linezolid. Clin Infect Dis 39:1010–1015. http://dx.doi.org/10.1086/423841.
248. Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 49:3554–3557. http://dx.doi.org/10.1128/AAC.49.8.3554-3557.2005.
249. Dong W, Chochua S, McGee L, Jackson D, Klugman KP, Vidal JE. 2014. Mutations within the rplD gene of linezolid-nonsusceptible Streptococcus pneumoniae strains isolated in the United States. Antimicrob Agents Chemother 58:2459–2462. http://dx.doi.org/10.1128/AAC.02630-13.
250. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Légaré D, Ouellette M. 2009. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19:1214–1223. http://dx.doi.org/10.1101/gr.089342.108.
251. Feng J, Billal DS, Lupien A, Racine G, Winstall E, Légaré D, Leprohon P, Ouellette M. 2011. Proteomic and transcriptomic analysis of linezolid resistance in Streptococcus pneumoniae. J Proteome Res 10:4439–4452. http://dx.doi.org/10.1021/pr200221s.
252. Kisgen JJ, Mansour H, Unger NR, Childs LM. 2014. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm 71:621–633. http://dx.doi.org/10.2146/ajhp130482.
253. Jones RN, Farrell DJ, Morrissey I. 2003. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 47:2696–2698. http://dx.doi.org/10.1128/AAC.47.8.2696-2698.2003.
254. Ford KL, Mason EO, Jr, Kaplan SL, Lamberth LB, Tillman J. 1991. Factors associated with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a children’s hospital. J Pediatr 119:941–944. http://dx.doi.org/10.1016/S0022-3476(05)83050-1.
255. Tan QT, Mason EO, Jr, Kaplan SL. 1993. Penicillin-resistant systemic pneumococcal infections in children: a retrospective case-control study. Pediatrics 92:761–767.
256. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, Bouvenot G, Eschwége E. 1998. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillinresistant Streptococcus pneumoniae. JAMA 279:365–370. http://dx.doi.org/10.1001/jama.279.5.365.
257. Reichler MR, Allphin AA, Breiman RF, Schreiber JR, Arnold JE, McDougal LK, Facklam RR, Boxerbaum B, May D, Walton RO. 1992. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 166:1346–1353. http://dx.doi.org/10.1093/infdis/166.6.1346.
258. Hsieh YC, Wang JT, Lee WS, Hsueh PR, Shao PL, Chang LY, Lu CY, Lee CY, Huang FY, Huang LM. 2006. Serotype competence and penicillin resistance in Streptococcus pneumoniae. Emerg Infect Dis 12:1709–1714. http://dx.doi.org/10.3201/eid1211.060414.
259. Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, McGee L, von Gottberg A, Song JH, Ko KS, Pichon B, Baker S, Parry CM, Lambertsen LM, Shahinas D, Pillai DR, Mitchell TJ, Dougan G, Tomasz A, Klugman KP, Parkhill J, Hanage WP, Bentley SD. 2011. Rapid pneumococcal evolution in response to clinical interventions. Science 331:430–434. http://dx.doi.org/10.1126/science.1198545.
260. Hanage WP, Fraser C, Tang J, Connor TR, Corander J. 2009. Hyperrecombination, diversity, and antibiotic resistance in pneumococcus. Science 324:1454–1457. http://dx.doi.org/10.1126/science.1171908.
261. Laurenceau R, Péhau-Arnaudet G, Baconnais S, Gault J, Malosse C, Dujeancourt A, Campo N, Chamot-Rooke J, Le Cam E, Claverys JP, Fronzes R. 2013. A type IV pilus mediates DNA binding during natural transformation in Streptococcus pneumoniae. PLoS Pathog 9:e1003473. http://dx.doi.org/10.1371/journal.ppat.1003473.
262. Prudhomme M, Attaiech L, Sanchez G, Martin B, Claverys JP. 2006. Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae. Science 313:89–92. http://dx.doi.org/10.1126/science.1127912.
263. Da Cunha V, Davies MR, Douarre PE, Rosinski-Chupin I, Margarit I, Spinali S, Perkins T, Lechat P, Dmytruk N, Sauvage E, Ma L, Romi B, Tichit M, Lopez-Sanchez MJ, Descorps-Declere S, Souche E, Buchrieser C, Trieu-Cuot P, Moszer I, Clermont D, Maione D, Bouchier C, McMillan DJ, Parkhill J, Telford JL, Dougan G, Walker MJ, DEVANI Consortium, Holden MT, Poyart C, Glaser P. 2014. Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nat Commun 5:4544. http://dx.doi.org/10.1038/ncomms5544.
264. Mills RO, Twum-Danso K, Owusu-Agyei S, Donkor ES. 2015. Epidemiology of pneumococcal carriage in children under five years of age in Accra, Ghana. Infect Dis (Lond) 47:326–331. http://dx.doi.org/10.3109/00365548.2014.994185.
265. Turner P, Turner C, Jankhot A, Helen N, Lee SJ, Day NP, White NJ, Nosten F, Goldblatt DA. 2012. Longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS One 7:e38271. http://dx.doi.org/10.1371/journal.pone.0038271.
266. Dhoubhadel BG, Yasunami M, Nguyen HA, Suzuki M, Vu TH, Thi Thuy Nguyen A, Dang DA, Yoshida LM, Ariyoshi K. 2014. Bacterial load of pneumococcal serotypes correlates with their prevalence and multiple serotypes is associated with acute respiratory infections among children less than 5 years of age. PLoS One 9:e110777. http://dx.doi.org/10.1371/journal.pone.0110777.
267. Otsuka T, Chang B, Shirai T, Iwaya A, Wada A, Yamanaka N, Okazaki M, SADO-study Working Group. 2013. Individual risk factors associated with nasopharyngeal colonization with Streptococcus pneumoniae and Haemophilus influenzae: a Japanese birth cohort study. Pediatr Infect Dis J 32:709–714. http://dx.doi.org/10.1097/INF.0b013e31828701ea.
268. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, Samore MH, Lipsitch M. 2003. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 9:424–430. http://dx.doi.org/10.1038/nm839.
269. Bjorkman J, Andersson DI. 2000. The cost of antibiotic resistance from a bacterial perspective. Drug Resist Updat 3:237–245. http://dx.doi.org/10.1054/drup.2000.0147.
270. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260–271. http://dx.doi.org/10.1038/nrmicro2319.
271. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489–493. http://dx.doi.org/10.1016/S1369-5274(99)00005-3.
272. Rozen DE, McGee L, Levin BR, Klugman KP. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 51:412–416. http://dx.doi.org/10.1128/AAC.01161-06.
273. Balsalobre L, de la Campa AG. 2008. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob Agents Chemother 52:822–830. http://dx.doi.org/10.1128/AAC.00731-07.
274. Rieux V, Carbon C, Azoulay-Dupuis E. 2001. Complex relationship between acquisition of β-lactam resistance and loss of virulence in Streptococcus pneumoniae. J Infect Dis 184:66–72. http://dx.doi.org/10.1086/320992.
275. Trzcinski K, Thompson CM, Gilbey AM, Dowson CG, Lipsitch M. 2006. Incremental increase in fitness cost with increased β-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J Infect Dis 193:1296–1303. http://dx.doi.org/10.1086/501367.
276. Albarracín Orio AG, Piñas GE, Cortes PR, Cian MB, Echenique J. 2011. Compensatory evolution of pbp mutations restores the fitness cost imposed by β-lactam resistance in Streptococcus pneumoniae. PLoS Pathog 7:e1002000. http://dx.doi.org/10.1371/journal.ppat.1002000.
277. Ortega M, Marco F, Soriano A, García E, Martínez JA, Mensa J. 2003. Lack of vancomycin tolerance in Streptococcus pneumoniae strains isolated in Barcelona, Spain, from 1999 to 2001. Antimicrob Agents Chemother 47:1976–1978. http://dx.doi.org/10.1128/AAC.47.6.1976-1978.2003.
278. Liu HH, Tomasz A. 1985. Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. J Infect Dis 152:365–372. http://dx.doi.org/10.1093/infdis/152.2.365.
279. McCullers JA, English BK, Novak R. 2000. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 181:369–373. http://dx.doi.org/10.1086/315216.
280. Mitchell L, Tuomanen E. 2001. Vancomycin-tolerant Streptococcus pneumoniae and its clinical significance. Pediatr Infect Dis J 20:531–533. http://dx.doi.org/10.1097/00006454-200105000-00012.
281. Olivares A, Trejo JO, Arellano-Galindo J, Zuñiga G, Escalona G, Vigueras JC, Marín P, Xicohtencatl J, Valencia P, Velázquez-Guadarrama N. 2011. pep27 and lytA in vancomycin-tolerant pneumococci. J Microbiol Biotechnol 21:1345–1351. http://dx.doi.org/10.4014/jmb.1105.05045.
282. Mascher T, Zahner D, Merai M, Balmelle N, De Saizieu AB, Hakenbeck R. 2003. The Streptococcus pneumoniae cia regulon: CiaR target sites and transcription profile analysis. J Bacteriol 185:60–70. http://dx.doi.org/10.1128/JB.185.1.60-70.2003.
283. Bourgeois I, Pestel-Caron M, Lemeland JF, Pons JL, Caron F. 2007. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase- negative staphylococci. Antimicrob Agents Chemother 51:740–743. http://dx.doi.org/10.1128/AAC.00719-06.
284. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. 1999. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399:590–593. http://dx.doi.org/10.1038/21202.
285. Sung H, Shin HB, Kim M-H, Lee K, Kim E-C, Song W, Jeong SH, Lee W-G, Park Y-J, Eliopoulos GM. 2006. Vancomycin-tolerant Streptococcus pneumoniae in Korea. J Clin Microbiol 44:3524–3528. http://dx.doi.org/10.1128/JCM.00558-06.
286. Novak R, Charpentier E, Braun JS, Tuomanen E. 2000. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol Cell 5:49–57. http://dx.doi.org/10.1016/S1097-2765(00)80402-5.
287. Chen Y, Deng W, Wang SM, Mo QM, Jia H, Wang Q, Li SG, Li X, Yao BD, Liu CJ, Zhan YQ, Ji C, Lopez AL, Wang XY. 2011. Burden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature review. PLoS One 6:e27333. http://dx.doi.org/10.1371/journal.pone.0027333.
288. Shi ZY, Enright MC, Wilkinson P, Griffiths D, Spratt BG. 1998. Identification of the three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequencing typing. J Clin Microbiol 36:3514–3519.
289. Hall LM, Whiley RA, Duke B, George RC, Efstratiou A. 1996. Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: analysis of multilocus enzyme electrophore- sis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns. J Clin Microbiol 34:853–859.
290. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall BW, Shelly MA, Mahon BE, Nahm MH. 2008. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 198:1818–1822. http://dx.doi.org/10.1086/593339.
291. Carvalho MDG, Pimenta FC, Gertz RE, Jr, Joshi HH, Trujillo AA, Keys LE, Findley J, Moura IS, Park IH, Hollingshead SK, Pilishvili T, Whitney CG, Nahm MH, Beall BW. 2009. PCR-based quantitation and clonal associations of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States: 1999, 2006-2007. J Clin Microbiol 47:554–559. http://dx.doi.org/10.1128/JCM.01919-08.
292. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH, Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG. 2015. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15:301–309. http://dx.doi.org/10.1016/S1473-3099(14)71081-3.
293. Pai R, Gertz RE, Whitney CG, Beall B. 2005. Clonal association between Streptococcus pneumoniae serotype 23A within the United States and an internationally dispersed clone of 23F. J Clin Microbiol 43:5440–5444. http://dx.doi.org/10.1128/JCM.43.11.5440-5444.2005.
294. Gertz RE, Jr, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, Jorgensen JH, Carvalho MDG, Beall BW. 2010. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 201:770–775. http://dx.doi.org/10.1086/650496.
295. Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. 2014. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother 58:4923–4927. http://dx.doi.org/10.1128/AAC.02976-14.
296. Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Carvalho MDC, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP. 2013. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J 32:e45–e53. http://dx.doi.org/10.1097/INF.0b013e3182788fdd.
297. Desai AP, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, Sherwood L, Zmitrovich A, Jerris R, Satola SW, Beall B, Moore MR, Jain S, Farley MM. 2015. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 34: 1168–1174. http://dx.doi.org/10.1097/INF.0000000000000849.
298. Hampton LM, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison LH, Lynfield R, Bennett NM, Petit S, Gershman K, Baumbach J, Beall B, Jorgensen J, Glennen A, Zell ER, Moore M. 2012. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 205:401–411. http://dx.doi.org/10.1093/infdis/jir755.
299. Moore MR. 2009. Rethinking replacement and resistance. J Infect Dis 199:771–773. http://dx.doi.org/10.1086/597045.
300. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI, Goldstein R, Huot H, Finkelstein JA. 2007. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 195:347–352. http://dx.doi.org/10.1086/510249.
301. Dagan R, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, Cohen T, Lipsitch M, Greenberg D. 2008. Seasonality of antibiotic-resistant Streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic- restriction policy? J Infect Dis 197:1094–1102. http://dx.doi.org/10.1086/528995.
302. Van Effelterre T, Moore MR, Fierens F, Whitney CG, White L, Pelton SI, Hausdorff WP. 2010. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 28:3650–3660. http://dx.doi.org/10.1016/j.vaccine.2010.03.030.
303. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, Vaccine Trialists Group. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349:1341–1348. http://dx.doi.org/10.1056/NEJMoa035060.
304. dos Santos SR, Passadore LF, Takagi EH, Fujii CM, Yoshioka CR, Gilio AE, Martinez MB. 2013. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation. Vaccine 31:6150–6154. http://dx.doi.org/10.1016/j.vaccine.2013.05.042.
305. Parra EL, De La Hoz F, Díaz PL, Sanabria O, Realpe ME, Moreno J. 2013. Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogota, Colombia. Vaccine 31:4033–4038. http://dx.doi.org/10.1016/j.vaccine.2013.04.074.
306. Regev-Yochay G, Rahav G, Riesenberg K, Wiener-Well Y, Strahilevitz J, Stein M, Glikman D, Weber G, Potasman I, Dagan R, IAIPD Study Group. 2014. Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel. PLoS One 9:e88406. http://dx.doi.org/10.1371/journal.pone.0088406.
307. Sham LT, Tsui HC, Land AD, Barendt SM, Winkler ME. 2012. Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets. Curr Opin Microbiol 15:194–203. http://dx.doi.org/10.1016/j.mib.2011.12.013.